Prescribing Pattern and Safety Profile of Biological Agents for Psoriasis in Real-World Practice: A Four-Year Calabrian Pharmacovigilance Analysis DOI Creative Commons
Caterina De Sarro, Francesca Bosco, Agnese Gagliardi

et al.

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(10), P. 1329 - 1329

Published: Oct. 14, 2024

The treatment of psoriasis has made considerable progress with biologicals, including tumor necrosis factor inhibitors, and recently, monoclonal antibodies inhibiting directly interleukin (IL) 17, IL-23, or both IL-12/23. Newer biologicals are directed to the pathway appear improve complete near-complete clearance. newer have also been shown an excellent safety profile. However, despite experience patients having confirmed results obtained in clinical trials, there still few data on using biologicals.

Language: Английский

Preclinical proof of principle for orally delivered Th17 antagonist miniproteins DOI Creative Commons
S. A. Berger,

Franziska Seeger,

Ta-Yi Yu

et al.

Cell, Journal Year: 2024, Volume and Issue: 187(16), P. 4305 - 4317.e18

Published: June 26, 2024

Interleukin (IL)-23 and IL-17 are well-validated therapeutic targets in autoinflammatory diseases. Antibodies targeting IL-23 have shown clinical efficacy but limited by high costs, safety risks, lack of sustained efficacy, poor patient convenience as they require parenteral administration. Here, we present designed miniproteins inhibiting IL-23R with antibody-like, low picomolar affinities at a fraction the molecular size. The minibinders potently block cell signaling vitro extremely stable, enabling oral administration low-cost manufacturing. orally administered minibinder shows better than anti-IL-23 antibody mouse colitis has favorable pharmacokinetics (PK) biodistribution profile rats. This work demonstrates that de novo-designed can reach target past gut epithelial barrier. With potency, stability, straightforward manufacturability, promising modality for biologics.

Language: Английский

Citations

20
Atopic dermatitis: treatment and innovations in immunotherapy DOI
Francesco Ferrara, Andrea Zovi, Maurizio Capuozzo

et al.

Inflammopharmacology, Journal Year: 2024, Volume and Issue: 32(3), P. 1777 - 1789

Published: April 6, 2024

Language: Английский

Citations

7
Psoriasis Treatments: Emerging Roles and Future Prospects of MicroRNAs DOI Creative Commons

Li Tian Keane Teo,

Nerissa Juantuah-Kusi,

Gowtham Subramanian

et al.

Non-Coding RNA, Journal Year: 2025, Volume and Issue: 11(1), P. 16 - 16

Published: Feb. 13, 2025

Psoriasis, a widespread and chronic inflammatory skin disorder, is marked by its persistence the lack of definitive cure. The pathogenesis psoriasis increasingly understood, with ongoing research highlighting intricate interplay genetic, immunological, environmental factors. Recent advancements have illuminated pivotal role microRNAs in orchestrating complex processes other hyperproliferative diseases. This narrative review highlights emerging significance miRNAs as key regulators examines their potential therapeutic targets. We discuss current treatment approaches promising future next-generation agents for this condition.

Language: Английский

Citations

0
Therapeutic Advancements in Psoriasis and Psoriatic Arthritis DOI Open Access

Robin C. Yi,

Maya Akbik, Logan R. Smith

et al.

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(4), P. 1312 - 1312

Published: Feb. 16, 2025

Background: Within the past few years, many new therapies have emerged for psoriasis and psoriatic arthritis (PsA). Current topical therapies-including corticosteroids, vitamin D analogs, tapinarof, roflumilast-remain mainstay mild disease, while oral systemic biologic options are moderate to severe cases. Biologics-such as Tumor necrosis factor-alpha (TNF-alpha), Interleukin 12/23 (IL-12/23), Interleukin-17 (IL-17), Interleukin-23 (IL-23)-have revolutionized care by providing highly effective safer alternatives. Oral small molecules, including Janus kinase (JAK) tyrosine 2 (TYK2) inhibitors, further expand therapeutic options. Objectives: The goal this review article was examine current latest treatments PsA discuss whether these emerging address unmet needs of treatments. Methods: search included PubMed, Google Scholar, ClinicalTrials.gov relevant articles clinical trials using keywords. Results: A wide range novel currently undergoing trials. These include selective JAK TYK2 retinoic acid-related orphan receptor (RORγT) IL-23 IL-17A nanobody products, sphingosine-1-phosphate (S1P1R) antagonists, A3 adenosine (A3AR) agonists, heat shock protein (HSP) 90 rho-associated kinases (ROCK-2) inhibitors. Conclusions: different mechanisms action not only treatment but may offer potential solutions patients who do achieve adequate response with existing therapies. However, safety contraindications newer agents remain an important consideration ensure appropriate patient selection minimize risks. Certain pose increased risks infection, cardiovascular manifestations, malignancy, or other immune-related adverse events, necessitating careful monitoring individualized decisions. Ongoing research aims respond previous sustained remission, monitor long-term outcomes, assess preferences delivery, a preference delivery. inhibitors hold due their robust profiles. In contrast, IL-17 TYK-2 present side effects that could impact acceptability. It is essential balance efficacy, safety, guide

Language: Английский

Citations

0
Live Probiotics-Loaded Delivery Systems for the Treatment of Infected Wounds DOI
Oksana Gerulis, Karin Kogermann

NATO science for peace and security series. A, Chemistry and biology, Journal Year: 2025, Volume and Issue: unknown, P. 51 - 78

Published: Jan. 1, 2025

Language: Английский

Citations

0
New and emerging oral therapies for psoriasis DOI Creative Commons
Orhan Yılmaz,

João Pedro Pinto,

Tiago Torres

et al.

Drugs in Context, Journal Year: 2024, Volume and Issue: 13, P. 1 - 24

Published: July 30, 2024

Psoriasis is a chronic inflammatory skin disease affecting 2-3% of the global population. Traditional systemic treatments, such as methotrexate, cyclosporine, acitretin and fumaric acid esters, have limited efficacy are associated with significant adverse effects, necessitating regular monitoring posing risks long-term toxicity. Recent advancements introduced biologic drugs that offer improved safety profiles. However, their high cost inconvenience parenteral administration limit accessibility. Consequently, there growing interest in developing new, targeted oral therapies. Small molecules, phosphodiesterase 4 inhibitors (e.g. apremilast) TYK2 inhibitor deucravacitinib), shown promising results favourable Additionally, other novel agents targeting specific pathways, including IL-17, IL-23, TNF, S1PR1 A3AR, under investigation. These treatments aim to combine biologics convenience accessibility administration, addressing limitations current This narrative review synthesizes emerging therapeutic for psoriasis, focusing on mechanisms action, stages development clinical trial results.

Language: Английский

Citations

3
Current therapeutic overview and future perspectives regarding the treatment of psoriasis DOI
Francesco Ferrara, Chiara Verduci,

Emanuela Laconi

et al.

International Immunopharmacology, Journal Year: 2024, Volume and Issue: 143, P. 113388 - 113388

Published: Oct. 14, 2024

Language: Английский

Citations

3
Chinese medicine as comprehensive therapy for psoriasis: A case report DOI Creative Commons

Lingjuan Liu,

Miao Li, Minhua Hu

et al.

Medicine, Journal Year: 2024, Volume and Issue: 103(48), P. e40747 - e40747

Published: Nov. 29, 2024

Rationale: Psoriasis is an immune-mediated, chronic, relapsing, inflammatory disease induced by a combination of genetic and environmental factors. It can be comorbid with other systemic diseases severely affects patient’s quality life. This case report describes the therapeutic role traditional Chinese medicine (TCM) in patient psoriasis. Patient concerns: The 32-year-old male exhibited symptoms increased dandruff recurrent erythematous scales on various body regions for nearly year. At same time, he had multisystemic metabolic abnormalities psychiatric disorders. Diagnosis: Severe plaque Interventions: was treated oral herbal only. Outcomes: Following TCM treatment, demonstrated significant improvement his skin condition metabolic-related indexes. Lessons: involved harmonization yin yang, regulation qi blood, dispersion pathogenic wind, cooling alleviation blood stasis. From modern medical perspective, prescriptions may address inflammation restoring physiological functions enhancing immune response. study illustrates efficacy treating disorders body’s internal environment.

Language: Английский

Citations

1
Enhancing Transcutaneous Drug Delivery: Advanced Perspectives on Skin Models DOI Creative Commons
Ana R. Ribeiro, Catarina Pereira‐Leite, Catarina Rosado

et al.

JID Innovations, Journal Year: 2024, Volume and Issue: 5(2), P. 100340 - 100340

Published: Dec. 17, 2024

Skin acts as a dynamic interface with the environment. Pathological alterations in skin barrier are associated diseases. These conditions characterized by specific impairments epidermal functions. Despite its protective nature, can be relevant route of drug administration, both for topical and transdermal therapy, allowing improved delivery reducing incidence adverse reactions. This manuscript reviews transcutaneous strategy treating localized systemic conditions, highlighting importance models evaluation efficacy function. It explores advances vitro, ex vivo, silico studying cellular uptake, wound healing, oxidative stress, anti-inflammatory, immune modulation activities. Disease-specific also discussed.

Language: Английский

Citations

1
The Epidemiology, Etiology, and Therapeutic Approaches of Psoriasis: A Review Article DOI Open Access

Maytham Adil,

Ali A. Al-fahham,

Nabaa Basim Alhusseini

et al.

INTERNATIONAL JOURNAL OF HEALTH & MEDICAL RESEARCH, Journal Year: 2024, Volume and Issue: 03(08)

Published: Aug. 31, 2024

Psoriasis is a common condition, affecting approximately 3-7% of the population in Western countries. It does not only affect skin, as buildup skin cells can also result development psoriatic arthritis that progresses to joint destruction. chronic condition over 60 million people worldwide. The incidence psoriasis varies globally, with some countries reporting rates low 0.1% and others high 11.8%. This review discusses detail different aspects related epidemiology, etiology, therapeutic approaches psoriasis.

Language: Английский

Citations

0